Cargando…
“Real‐world” eligibility for aducanumab depends on clinical setting and patients' journey
See related editorial by Lundebjerg et al.
Autores principales: | Padovani, Alessandro, Caratozzolo, Salvatore, Rozzini, Luca, Pilotto, Andrea, Benussi, Alberto, Tedeschi, Gioacchino |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298825/ https://www.ncbi.nlm.nih.gov/pubmed/34750815 http://dx.doi.org/10.1111/jgs.17530 |
Ejemplares similares
-
Public opinion regarding U.S. Food and Drug Administration approval of aducanumab and potential policy responses: A nationally representative survey
por: DiStefano, Michael J., et al.
Publicado: (2022) -
The role of light-harvesting complex I in excitation energy transfer from LHCII to photosystem I in Arabidopsis
por: Schiphorst, Christo, et al.
Publicado: (2021) -
PRIME‐HF: Novel Exercise for Older Patients with Heart Failure. A Pilot Randomized Controlled Study
por: Giuliano, Catherine, et al.
Publicado: (2020) -
Long‐Term Survival and Risk of Institutionalization in Onco‐Geriatric Surgical Patients: Long‐Term Results of the PREOP Study
por: Huisman, Monique G., et al.
Publicado: (2020) -
Interplay between Socioeconomic Markers and Polygenic Predisposition on Timing of Dementia Diagnosis
por: Ajnakina, Olesya, et al.
Publicado: (2020)